Laser Focus World is an industry bedrock—first published in 1965 and still going strong. We publish original articles about cutting-edge advances in lasers, optics, photonics, sensors, and quantum technologies, as well as test and measurement, and the shift currently underway to usher in the photonic integrated circuits, optical interconnects, and copackaged electronics and photonics to deliver the speed and efficiency essential for data centers of the future.

Our 80,000 qualified print subscribers—and 130,000 12-month engaged online audience—trust us to dive in and provide original journalism you won’t find elsewhere covering key emerging areas such as laser-driven inertial confinement fusion, lasers in space, integrated photonics, chipscale lasers, LiDAR, metasurfaces, high-energy laser weaponry, photonic crystals, and quantum computing/sensors/communications. We cover the innovations driving these markets.

Laser Focus World is part of Endeavor Business Media, a division of EndeavorB2B.

Laser Focus World Membership

Never miss any articles, videos, podcasts, or webinars by signing up for membership access to Laser Focus World online. You can manage your preferences all in one place—and provide our editorial team with your valued feedback.

Magazine Subscription

Can you subscribe to receive our print issue for free? Yes, you sure can!

Newsletter Subscription

Laser Focus World newsletter subscription is free to qualified professionals:

The Daily Beam

Showcases the newest content from Laser Focus World, including photonics- and optics-based applications, components, research, and trends. (Daily)

Product Watch

The latest in products within the photonics industry. (9x per year)

Bio & Life Sciences Product Watch

The latest in products within the biophotonics industry. (4x per year)

Laser Processing Product Watch

The latest in products within the laser processing industry. (3x per year)

Get Published!

If you’d like to write an article for us, reach out with a short pitch to Sally Cole Johnson: [email protected]. We love to hear from you.

Photonics Hot List

Laser Focus World produces a video newscast that gives a peek into what’s happening in the world of photonics.

Following the Photons: A Photonics Podcast

Following the Photons: A Photonics Podcast dives deep into the fascinating world of photonics. Our weekly episodes feature interviews and discussions with industry and research experts, providing valuable perspectives on the issues, technologies, and trends shaping the photonics community.

Editorial Advisory Board

  • Professor Andrea M. Armani, University of Southern California
  • Ruti Ben-Shlomi, Ph.D., LightSolver
  • James Butler, Ph.D., Hamamatsu
  • Natalie Fardian-Melamed, Ph.D., Columbia University
  • Justin Sigley, Ph.D., AmeriCOM
  • Professor Birgit Stiller, Max Planck Institute for the Science of Light, and Leibniz University of Hannover
  • Professor Stephen Sweeney, University of Glasgow
  • Mohan Wang, Ph.D., University of Oxford
  • Professor Xuchen Wang, Harbin Engineering University
  • Professor Stefan Witte, Delft University of Technology

Incyclix Bio Announces Publication in Nature Communications Highlighting Biomarkers of Response to CDK2 Inhibition

RESEARCH TRIANGLE PARK, N.C., Feb. 13, 2025 (GLOBE NEWSWIRE) -- Incyclix Bio, LLC, a next-generation cell cycle control company developing INX-315, a novel, potent and selective CDK2 inhibitor for the treatment of advanced and resistant cancer, today announced the publication of a peer-reviewed article in Nature Communications. The publication titled, “Discrete vulnerability to pharmacological CDK2 inhibition is governed by heterogeneity of the cancer cell cycle” identifies biomarkers for response to INX-315 and highlights the potential of INX-315 to overcome resistance to CDK4/6 inhibitors in certain cancers.

The publication outlines the analysis of DEPMAP data utilizing the CHRONOS score to distinguish cell response based on their dependencies to cyclins and CDKs that regulate the G1 to S phase transition. This analysis segregated cell lines into distinct clusters demonstrating specific dependencies on various cyclin and CDK genes, revealing tumor types that are exceptionally dependent on CDK2 and more sensitive to the INX-315 CDK2 inhibitor.

“We found that pharmacologically targeting a single kinase, CDK2, can trigger two distinct cellular responses depending on the tumor type,” said Vishnu Kumarasamy, PhD, first author on the new study and a Research Assistant Professor of Oncology in Roswell Park’s Department of Molecular & Cellular Biology.

Based on the results of the analysis, a broader range of tumors, including both breast and pancreatic cancer models, respond to CDK2 inhibitors.

“We hope these findings with CDK2 inhibitors in preclinical models will be translated into new clinical trials to help breast cancer patients whose disease has progressed on CDK4/6 inhibitors — and provide new opportunities in multiple additional cancers,” said Agnieszka Witkiewicz, MD, Director of the Advanced Tissue Imaging Shared Resource at Roswell Park and co-corresponding author of the study.

The study findings show potential for INX-315 in combination with CDK4/6 inhibitors to extend the therapeutic applicability of INX-315 beyond CDK2-addicted tumor types.

“By leveraging cell cycle biomarkers, we hope to be able to identify patients that will benefit most from combination treatments,” said Patrick Roberts, PharmD, PhD, Chief Executive Officer and Co-Founder of Incyclix Bio. “These striking new findings validate the combination of INX-315 with CDK4/6 inhibitors as a promising therapeutic strategy with potential application beyond patients with CDK2-addicted cancers.”

INX-315 monotherapy and combination dose-expansion clinical trials are ongoing. More information on the trial can be found at clinicaltrials.gov.

About Incyclix Bio

Incyclix Bio is a next-generation cell cycle control company advancing precision treatments that target the aberrant proliferation driving many cancers. The company’s lead compound, INX-315, is a potent and selective cyclin-dependent kinase 2 (CDK2) inhibitor in clinical development. Incyclix Bio is a scientific leader in understanding cyclin-dependent kinases (CDKs) and their role in the cell cycle as attractive therapeutic targets across many tumor types, including ovarian, breast and lung cancers. Headquartered in Research Triangle Park, NC, Incyclix Bio is founded by pioneers in CDK inhibitor discovery, research and development. For more information, visit incyclixbio.com.

Media Contact
Tony Plohoros
908-591-2839
tplohoros@6degreespr.com


Primary Logo

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.